This trial is active not recruiting!
Search for a recruiting clinical trial for your condition
Your journey
1What's a trial
4Get in touch
More info
You can access this
clinical trial
if you have
Non-Hodgkin's Lymphoma, Hodgkin Lymphoma or Multiple Myeloma
and you are
over 18
years old
This is a medium phase trial determining
the safety and dosage of the new treatment, as well as its efficacy.
Show me locations

The purpose

The purpose of this study is to determine the side effects of treatment of the combination of nivolumab and daratumumab in participants with relapsed/refractory multiple myeloma.

Provided treatments

  • Biological: Nivolumab
  • Biological: Ipilimumab
  • Biological: Lirilumab
  • Biological: Daratumumab
  • Drug: Pomalidomide
  • Drug: Dexamethasone

Locations near you

Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Tris trial is registered with FDA with number: NCT01592370. The sponsor of the trial is Bristol Myers Squibb and it is looking for 323 volunteers for the current phase.
Official trial title:
Multiple Phase 1/2 Cohorts of Nivolumab Monotherapy or Nivolumab Combination Regimens Across Relapsed/Refractory Hematologic Malignancies